Oliver G. Ottmann

26.7k total citations · 4 hit papers
372 papers, 16.1k citations indexed

About

Oliver G. Ottmann is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Oliver G. Ottmann has authored 372 papers receiving a total of 16.1k indexed citations (citations by other indexed papers that have themselves been cited), including 297 papers in Hematology, 135 papers in Genetics and 101 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Oliver G. Ottmann's work include Chronic Myeloid Leukemia Treatments (176 papers), Acute Myeloid Leukemia Research (117 papers) and Chronic Lymphocytic Leukemia Research (114 papers). Oliver G. Ottmann is often cited by papers focused on Chronic Myeloid Leukemia Treatments (176 papers), Acute Myeloid Leukemia Research (117 papers) and Chronic Lymphocytic Leukemia Research (114 papers). Oliver G. Ottmann collaborates with scholars based in Germany, United States and United Kingdom. Oliver G. Ottmann's co-authors include Dieter Hoelzer, Arnold Ganser, Gesine Bug, Andreas Hochhaus, Barbara Waßmann, D. Hoelzer, Roman Pfeifer, Hagop M. Kantarjian, Francis J. Giles and Jörge E. Cortes and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Oliver G. Ottmann

366 papers receiving 15.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Lydia Wunderle, Kapil N. Bhalla et al. profile →
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

2018 354 citations Oliver G. Ottmann et al. profile →
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

2017 298 citations Giovanni Martinelli, Nicolas Boissel et al. Journal of Clinical Oncology profile →
Management of ALL in adults: 2024 ELN recommendations from a European expert panel

2024 45 citations Nicola Gökbuget, Nicolas Boissel et al. Blood profile →

Peers

Countries citing papers authored by Oliver G. Ottmann

Since Specialization

Citations

This map shows the geographic impact of Oliver G. Ottmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Oliver G. Ottmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Oliver G. Ottmann more than expected).

Fields of papers citing papers by Oliver G. Ottmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Oliver G. Ottmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Oliver G. Ottmann. The network helps show where Oliver G. Ottmann may publish in the future.

Co-authorship network of co-authors of Oliver G. Ottmann

This figure shows the co-authorship network connecting the top 25 collaborators of Oliver G. Ottmann. A scholar is included among the top collaborators of Oliver G. Ottmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Oliver G. Ottmann. Oliver G. Ottmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia 2025 ·Leukemia & lymphoma ·Fabian Lang, Andreas Voß, Guido Kobbe, Christian Junghanß, Joachim Beck, Andreas Viardot, Knut Wendelin, Jens Panse, (unknown), Vladan Vučinić, Boris Böll, Max S. Topp, (unknown), Hubert Serve, Nicola Goekbuget, Oliver G. Ottmann, Roman Pfeifer	0
2	Understanding a high-risk acute myeloid leukemia by analyzing the interactome of its major driver mutation 2022 ·PLoS Genetics ·(unknown), (unknown), (unknown), (unknown), (unknown), Caroline Alvares, Dörte Becher, Paul S. Hole, Oliver G. Ottmann, Martin Ruthardt	5
3	A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia 2020 ·BMC Pharmacology and Toxicology ·Fabian Lang, Lydia Wunderle, (unknown), Eberhard Schleyer, Monika Brüggemann, Hubert Serve, Susanne Schnittger, Nicola Gökbuget, Roman Pfeifer, Sebastian Wagner, Kevin E. Ashelford, Gesine Bug, Oliver G. Ottmann	28
4	Clinicians’ Perspectives on Cure in Adult Patients with Acute Lymphoblastic Leukemia with Minimal Residual Disease: A Delphi Study 2019 ·Advances in Therapy ·Wendy Gidman, (unknown), Lirong Zhang, Jan McKendrick, Ze Cong, David Cohan, Oliver G. Ottmann	5
5	Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study breakdown → 2017 ·Journal of Clinical Oncology ·Giovanni Martinelli, Nicolas Boissel, Patrice Chevallier, Oliver G. Ottmann, Nicola Gökbuget, Max S. Topp, Adele K. Fielding, Alessandro Rambaldi, Ellen K. Ritchie, Cristina Papayannidis, Lulu Ren Sterling, Jonathan Benjamin, Anthony S. Stein	298
6	Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy 2017 ·Blood ·Inga Nagel, Marius Bartels, Johannes Duell, Hans‐Heinrich Oberg, Sandra Ussat, Henrike Bruckmueller, Oliver G. Ottmann, Roman Pfeifer, Heiko Trautmann, Nicola Gökbuget, Almuth Caliebe, Dieter Kabelitz, Michael Kneba, Heinz‐August Horst, Dieter Hoelzer, Max S. Topp, Ingolf Cascorbi, Reiner Siebert, Monika Brüggemann	63
7	Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study 2015 ·Blood ·Aristoteles Giagounidis, Uwe Platzbecker, Ulrich Germing, Katharina S. Götze, Philipp Kiewe, Karin Mayer, Oliver G. Ottmann, Markus P. Radsak, Thomas Wolff, Detlef Haase, (unknown), Dawn Wilson, Xiaosha Zhang, (unknown), Matthew L. Sherman, Kenneth M. Attie	22
8	Knockdown of ERM Family Member Moesin in Host Cells Increases HIV Type 1 Replication 2011 ·AIDS Research and Human Retroviruses ·Gianni Capalbo, (unknown), (unknown), Stefan Klein, Ursula Dietrich, Dieter Hoelzer, Oliver G. Ottmann, Urban Scheuring	8
9	PANOBINOSTAT HAS ACTIVITY IN TREATMENT-REFRACTORY HODGKIN LYMPHOMA 2009 ·(unknown), Andrew Spencer, Oliver G. Ottmann, (unknown), Thomas Kindler, Kapil N. Bhalla, (unknown), (unknown), (unknown), (unknown), Edward Ashton, (unknown), Glen Laird, (unknown), H. Miles Prince	3
10	Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement 2008 ·Cancer Genetics and Cytogenetics ·(unknown), Károly Szuhai, J.H. Frederik Falkenburg, Marianke L.J. van Schie, Oliver G. Ottmann, Bart Nijmeijer	15
11	Targeting the Oligomerization Domain of ETO Interferes with RUNX1/ETO Oncogenic Activity in t(8;21)-Positive Leukemic Cells 2007 ·Cancer Research ·Christian Wichmann, Linping Chen, Markus R. Heinrich, Daniela Baus, Edith Pfitzner, Martin Zörnig, Oliver G. Ottmann, Manuel Grez	31
12	Analysis of T(9;22) breakpoints indicates that P210 and P190 BCR-ABL are formed by distinct mechanisms 2007 ·ePrints Soton (University of Southampton) ·J Score, Marı́a José Calasanz, Fabrizio Pane, Oliver G. Ottmann, Francis Grand, Nicholas C.P. Cross	1
13	Clinical trial of valproic acid and all‐trans retinoic acid in patients with poor‐risk acute myeloid leukemia 2005 ·Cancer ·Gesine Bug, Markus Ritter, Barbara Waßmann, Claudia Schoch, Thorsten Heinzel, K. Schwarz, A Romański, Oliver H. Krämer, Manuela Kampfmann, Dieter Hoelzer, Andreas Neubauer, Martin Ruthardt, Oliver G. Ottmann	154
14	Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia 2004 ·Annals of Hematology ·W.-K. Hofmann, Gerhard Heil, (unknown), Stephanie A. Wiebe, Oliver G. Ottmann, Lothar Bergmann, Klaus Hoeffken, J. Th. Fischer, Alexander Knuth, Karin Kolbe, Hans‐Joachim Schmoll, Wolfgang Langer, M. Westerhausen, (unknown), D. Hoelzer, Arnold Ganser	44
15	Mobilization and Transduction of CD34 ⁺ Peripheral Blood Stem Cells in Patients with X-Linked Chronic Granulomatous Disease 2002 ·Journal of Hematotherapy & Stem Cell Research ·(unknown), (unknown), Oliver G. Ottmann, Hans Martin, (unknown), (unknown), Reinhard Seger, Johann Peter Hossle, Dieter Hoelzer, Manuel Grez	7
16	IL-18 Activates STAT3 in the Natural Killer Cell Line 92, Augments Cytotoxic Activity, and Mediates IFN-γ Production by the Stress Kinase p38 and by the Extracellular Regulated Kinases p44 erk-1 and p42 erk-2 1 2000 ·The Journal of Immunology ·Uwe Kalina, (unknown), Noriko Koyama, (unknown), (unknown), Steffen Koschmieder, Gesine Bug, Wolf‐Karsten Hofmann, Dieter Hoelzer, Oliver G. Ottmann	122
17	Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding. 1998 ·PubMed ·Greg Stratmann, Shirley Harder, (unknown), W-K Hofmann, Oliver G. Ottmann, (unknown)	1
18	Influence of Human Recombinant Interferon-Alpha and Interferon-Gamma on Bone Marrow Progenitor Cells of HIV-Positive Individuals 1992 ·AIDS Research and Human Retroviruses ·R. G. Geißler, Oliver G. Ottmann, G. Kojouharoff, (unknown), M Eder, D. Hoelzer, Arnold Ganser	14
19	TIBO R82913, A New HIV-1 Inhibiting Agent, Does Not Inhibit Hematopoietic Progenitor Cells 1991 ·AIDS Research and Human Retroviruses ·R. G. Geißler, Arnold Ganser, Oliver G. Ottmann, G. Kojouharoff, (unknown), Koen Andries, K H Schellekens, D. Hoelzer	1
20	Effects of recombinant human IL-7 on blast cell proliferation in acute lymphoblastic leukemia. 1990 ·PubMed ·M Eder, Oliver G. Ottmann, TE Hansen-Hagge, (unknown), S Gillis, D. Hoelzer, Arnold Ganser	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact